KCAS Bio will be participating in Society for Immunotherapy of Cancer (SITC) 2025, taking place on November 5-9 in National Harbor, MD.
SITC 2025 convenes researchers, clinicians, and biopharmaceutical developers to explore the latest breakthroughs in immune-based cancer treatments. These field experts will discuss cutting-edge research and clinical needs within immuno-oncology, such as new checkpoint inhibitors, cancer vaccines, cell and gene therapies, and more. With a dynamic agenda of speaker sessions and exhibits, SITC 2025 will foster meaningful collaboration across disciplines. This open exchange of ideas is vital to advancing translational research and shaping the next generation of immuno-oncology breakthroughs.
Immunotherapy at KCAS Bio
KCAS Bio has deep experience in immunology, oncology, and regulatory science that allows us to support the unique demands of any immuno-oncology study. Our expertise enables us to tailor our bioanalytical solutions based on study needs, including combination therapies and cell and gene therapies. Our key solutions, immunogenicity assessment, biomarker development, and custom assay design make us a dynamic organization- ready to adapt to any emerging modality.
Evolving with Innovation
KCAS Bio is committed to advancing the future of cancer research by remaining actively engaged in the evolving landscape of immuno-oncology. Through ongoing participation in leading scientific conferences and collaboration with industry innovators, we continuously refine our approaches, integrate new technologies, and adapt our strategies to meet the needs of tomorrow’s therapies.
Come See Us
We invite you to stop by our exhibit and meet with us throughout SITC 2025. Our team will be ready to engage in any discussion regarding the development of immunotherapies. Learn how KCAS Bio can tailor our solutions to support any complex project.